Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
Explore this paper's citation graph
Summary
Patients treated with canagliflozin had a lower risk of cardiovascular events than those who received placebo but a greater risk of amputation, primarily at the level of the toe or metatarsal.
- Type
- article
- Published
- 2017-06-12
- Cited by
- 3,924
- References
- 24
- Access
- Open access
- OpenAlex
- https://openalex.org/W2626446274
- Semantic Scholar
- https://api.semanticscholar.org/CorpusID:205101006
Keywords
Canagliflozin, Albuminuria, Medicine, Blood pressure, Type 2 diabetes
References
- Atrial natriuretic peptide and the kidney.
- Renal Hemodynamic Effect of Sodium-Glucose Cotransporter 2 Inhibition in Patients With Type 1 Diabetes Mellitus
- Elevated plasma atrial natriuretic peptide levels in diabetic rats. Potential mediator of hyperfiltration.
- Effects of intensive blood pressure lowering on the progression of chronic kidney disease: a systematic review and meta-analysis
- Rationale, design, and baseline characteristics of the Canagliflozin Cardiovascular Assessment Study (CANVAS)--a randomized placebo-controlled trial.
- Blood pressure lowering in type 2 diabetes: a systematic review and meta-analysis.
- Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study
- Worldwide access to treatment for end-stage kidney disease: a systematic review.
- Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes.
- The glycocalyx—linking albuminuria with renal and cardiovascular disease
- Intensive glucose control improves kidney outcomes in patients with type 2 diabetes.
- Effects of Canagliflozin on Fracture Risk in Patients With Type 2 Diabetes Mellitus.
- Effects of sodium-glucose cotransporter-2 inhibitors on cardiovascular events, death, and major safety outcomes in adults with type 2 diabetes: a systematic review and meta-analysis.
- Long-term Benefits of Intensive Glucose Control for Preventing End-Stage Kidney Disease: ADVANCE-ON
- Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes.
- SGLT-2 inhibitors: Their pleiotropic properties.
- Optimizing the analysis strategy for the CANVAS Program: A prespecified plan for the integrated analyses of the CANVAS and CANVAS‐R trials
- Effects of intensive glucose control on microvascular outcomes in patients with type 2 diabetes: a meta-analysis of individual participant data from randomised controlled trials.
- Rationale, design and baseline characteristics of the CANagliflozin cardioVascular Assessment Study–Renal (CANVAS‐R): A randomized, placebo‐controlled trial
- Regression models and life tables (with discussion
Cited by
- SGLT2 inhibitors in type 1 diabetes: knocked down, but up again?
- Renal outcomes with dipeptidyl peptidase-4 inhibitors.
- Impacts of sodium-glucose co-transporter type 2 inhibitors on central blood pressure
- SGLT2 inhibitors with cardiovascular benefits: Transforming clinical care in Type 2 diabetes mellitus.
- Cardiovascular Events Associated With SGLT-2 Inhibitors Versus Other Glucose-Lowering Drugs: The CVD-REAL 2 Study.
- Dissonance among treatment algorithms for hyperglycemia in type 2 diabetes: an egalitarian dialog
- Unexplained reciprocal regulation of diabetes and lipoproteins
- Dual inhibition of sodium–glucose linked cotransporters 1 and 2 exacerbates cardiac dysfunction following experimental myocardial infarction
- Comparison of healthcare resource utilization and costs in patients with type 2 diabetes initiating dapagliflozin versus sitagliptin
- Revisiting the Diabetes-Heart Failure Connection
- Primary Prevention of Heart Failure in Women.
- Ambulatory Blood Pressure Reduction With SGLT-2 Inhibitors: Dose-Response Meta-analysis and Comparative Evaluation With Low-Dose Hydrochlorothiazide
- Albuminuria-lowering effect of dapagliflozin alone and in combination with saxagliptin and effect of dapagliflozin and saxagliptin on glycaemic control in patients with type 2 diabetes and chronic kidney disease (DELIGHT): a randomised, double-blind, placebo-controlled trial.
- Analysis from the EMPA-REG OUTCOME® trial indicates empagliflozin may assist in preventing the progression of chronic kidney disease in patients with type 2 diabetes irrespective of medications that alter intrarenal hemodynamics.
- Sodium‐glucose linked transporter‐2 inhibitor renal outcome modification in type 2 diabetes: Evidence from studies in patients with high or low renal risk
- Clinical evidence and treatment requirements related to heart failure in type 2 diabetes mellitus.
- Interpreting the results of the VERTIS‐CV trial: Is this the end of the “class effect” perspective?
- 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD.
- CONSENSUS STATEMENT BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY ON THE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM--2016 EXECUTIVE SUMMARY.
- Iron management in chronic kidney disease: conclusions from a "Kidney Disease: Improving Global Outcomes" (KDIGO) Controversies Conference.
Related papers
- Update on SGLT2 Inhibitors-New Data Released at the American Diabetes Association.
- Differentiating the Sodium‐Glucose Cotransporter 1 Inhibition Capacity of Canagliflozin vs. Dapagliflozin and Empagliflozin Using Quantitative Systems Pharmacology Modeling
- Comparison of Canagliflozin, Dapagliflozin and Empagliflozin Added to Heart Failure Treatment in Decompensated Heart Failure Patients With Type 2 Diabetes Mellitus
- Comprehensive List of DACA Drugs
- Abstract 207: Cardiovascular Outcomes of Sodium-glucose Co-transporter 2 Inhibitors: A Meta-analysis
- Does lower limb amputation concern all SGLT2 inhibitors?
- The role of SGLT2 inhibitors in managing type 2 diabetes